Alexander I. Kaminnyi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alexander I. Kaminnyi has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
G. G. Konovalova
Russian Ministry of Health
6 shared publicationsV. V. Kukharchuk
Federal Agency of Health Care and Social Development
6 shared publicationsA. K. Tikhaze
Russian Ministry of Health
5 shared publications- Yulia A. Shuvalova
FSBI Academician E I Chazov National Medical Research Centre of Cardiology of the Ministry of Health of the Russian Federation, Department of Atherosclerosis Problems, 3rd Cherepkovskaya str, 15a, Moscow 121552, Russia
5 shared publications - Anatoliy N. Samko
National Medical Research Center of Cardiology
4 shared publications V. Z. Lankin
Russian Ministry of Health
4 shared publications
Latest Publications
- 25 December 2025
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 20 (4)
Inflammation in pathogenesis of cardiovascular diseases and prospects for targeted anti-inflammatory therapy
Chronic inflammation is an independent risk factor of atherosclerosis and cardiovascular diseases (CVD). The initiator of this process is innate immune response through activation of pro-inflammatory cytokines — interleukin-1β (IL-1β) and interleukin-6 (IL-6). This review discusses current concepts of the role of inflammation in pathogenesis of atherosclerosis, focusing on IL-6 signaling pathways, its soluble receptor (sIL-6R) and glycoprotein 130 (gp130), as well as of C-reactive protein (CRP) as clinical biomarker of inflammation. Evidence on the role of inflammation obtained from various studies is reviewed. Special attention is paid to prospects of targeted anti-inflammatory therapy, including inhibition of IL-1β pathway, global inhibition of IL-6, and selective blocking of its trans-signaling pathway using soluble gp130 (sgp130). This would likely suppress pathological inflammation in atherosclerosis while preserving cytokine’s important protective functions and will become a key objective of future research.
- 25 December 2025
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 20 (4)
Inflammation in pathogenesis of cardiovascular diseases and prospects for targeted anti-inflammatory therapy
Chronic inflammation is an independent risk factor of atherosclerosis and cardiovascular diseases (CVD). The initiator of this process is innate immune response through activation of pro-inflammatory cytokines — interleukin-1β (IL-1β) and interleukin-6 (IL-6). This review discusses current concepts of the role of inflammation in pathogenesis of atherosclerosis, focusing on IL-6 signaling pathways, its soluble receptor (sIL-6R) and glycoprotein 130 (gp130), as well as of C-reactive protein (CRP) as clinical biomarker of inflammation. Evidence on the role of inflammation obtained from various studies is reviewed. Special attention is paid to prospects of targeted anti-inflammatory therapy, including inhibition of IL-1β pathway, global inhibition of IL-6, and selective blocking of its trans-signaling pathway using soluble gp130 (sgp130). This would likely suppress pathological inflammation in atherosclerosis while preserving cytokine’s important protective functions and will become a key objective of future research.
- 1 September 2013
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 14 (5) , 284-288
Two-year follow-up of percutaneous coronary intervention using EucaTax or Cypher
- 1 September 2013
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 14 (5) , 284-288
Two-year follow-up of percutaneous coronary intervention using EucaTax or Cypher
- 14 August 2012
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 370 (1-2) , 241-249
Association between polymorphisms of eNOS and GPx-1 genes, activity of free-radical processes and in-stent restenosis
Our aim was to examine correlations between polymorphisms in five antioxidant enzymes genes, activity of free-radical processes, and the risk of restenosis after coronary artery stenting with bare metal stents (BMS). A total of 101 male patients who underwent intracoronary stenting using BMS and coronary angiography follow-up of 6 months were enrolled in: group with in-stent restenosis (n = 44) and without restenosis (n = 57). The content of lipoperoxides and malondialdehyde (MDA) in Low-density lipoprotein (LDL), activity of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) in erythrocytes, and genotypes polymorphisms of the CAT gene (−262C/T), paraoxonase-1 (PON-1) gene (163T/A and 575A/G), endothelial nitric oxide synthase (eNOS) gene (298G/T (rs#1799983) and −786T/C), GPx-1 gene (599C/T (rs#1050450)), and glutathione-S-transferase (GSTP) gene (313A/G) were determined. In carriers of the minor allele of 599C/T polymorphism of the GPx-1 gene, activity of GPx in erythrocytes was lower by 17 % than in wild allele homozygotes, while the content of lipoperoxides in LDL was higher by 74 %. T-allele of 599C/T polymorphism of the GPx-1 gene (OR = 2.9; 95 % CI: 1.23–6.82) and T-allele of 298G/T polymorphism of the eNOS gene (OR = 2.79; 95 % CI: 1.17–6.66) were associated with the risk of in-stent restenosis. Minor alleles of polymorphisms 298G/T of the eNOS gene and 599C/T of the GPx-1 gene are associated with an increased risk of in-stent restenosis. Minor allele of the GPx-1 gene 599C/T polymorphism leads to a decrease of the GPx activity and increase of the activity of free-radical processes.
- 14 August 2012
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 370 (1-2) , 241-249
Association between polymorphisms of eNOS and GPx-1 genes, activity of free-radical processes and in-stent restenosis
Our aim was to examine correlations between polymorphisms in five antioxidant enzymes genes, activity of free-radical processes, and the risk of restenosis after coronary artery stenting with bare metal stents (BMS). A total of 101 male patients who underwent intracoronary stenting using BMS and coronary angiography follow-up of 6 months were enrolled in: group with in-stent restenosis (n = 44) and without restenosis (n = 57). The content of lipoperoxides and malondialdehyde (MDA) in Low-density lipoprotein (LDL), activity of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) in erythrocytes, and genotypes polymorphisms of the CAT gene (−262C/T), paraoxonase-1 (PON-1) gene (163T/A and 575A/G), endothelial nitric oxide synthase (eNOS) gene (298G/T (rs#1799983) and −786T/C), GPx-1 gene (599C/T (rs#1050450)), and glutathione-S-transferase (GSTP) gene (313A/G) were determined. In carriers of the minor allele of 599C/T polymorphism of the GPx-1 gene, activity of GPx in erythrocytes was lower by 17 % than in wild allele homozygotes, while the content of lipoperoxides in LDL was higher by 74 %. T-allele of 599C/T polymorphism of the GPx-1 gene (OR = 2.9; 95 % CI: 1.23–6.82) and T-allele of 298G/T polymorphism of the eNOS gene (OR = 2.79; 95 % CI: 1.17–6.66) were associated with the risk of in-stent restenosis. Minor alleles of polymorphisms 298G/T of the eNOS gene and 599C/T of the GPx-1 gene are associated with an increased risk of in-stent restenosis. Minor allele of the GPx-1 gene 599C/T polymorphism leads to a decrease of the GPx activity and increase of the activity of free-radical processes.
- 28 October 2010
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 149 (6) , 743-745
Pro198Leu polymorphism of GPx-1 gene and activity of erythrocytic glutathione peroxidase and lipid peroxidation products.
- 28 October 2010
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 149 (6) , 743-745
Pro198Leu polymorphism of GPx-1 gene and activity of erythrocytic glutathione peroxidase and lipid peroxidation products.
- 1 November 2007
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 144 (5) , 664-666
Relationship between free-radical lipid oxidation and efficiency of coronary angioplasty in coronary patients
Low-dose (250 mg daily) oral probucol produces a significant antioxidant effect in coronary patients: increases activity of glutathione peroxidase (enzyme utilizing lipoperoxides) and reduces the content of free-radical oxidation products in the blood. Probucol therapy for 7 days before and for 6 months after coronary angioplasty significantly reduces the severity of coronary artery stenosis.
- 1 November 2007
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 144 (5) , 664-666
Relationship between free-radical lipid oxidation and efficiency of coronary angioplasty in coronary patients
Low-dose (250 mg daily) oral probucol produces a significant antioxidant effect in coronary patients: increases activity of glutathione peroxidase (enzyme utilizing lipoperoxides) and reduces the content of free-radical oxidation products in the blood. Probucol therapy for 7 days before and for 6 months after coronary angioplasty significantly reduces the severity of coronary artery stenosis.
- 1 April 2007
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 143 (4) , 414-417
Effect of β-hydroxy-β-methylglutaryl coenzyme a reductase inhibitors and antioxidant vitamins on free radical lipid oxidation in rat liver
- 1 April 2007
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 143 (4) , 414-417
Effect of β-hydroxy-β-methylglutaryl coenzyme a reductase inhibitors and antioxidant vitamins on free radical lipid oxidation in rat liver
- 1 April 2007
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 143 (4) , 408-410
Effect of β-hydroxy-β-methylglutaryl coenzyme a reductase inhibitor atorvastatin on contractility of the isolated rat heart under normal conditions and during oxidative stress
Long-term administration of β-hydroxy-β-methylglutaryl coenzyme A reductase inhibitor atorvastatin to rats was accompanied by an increase in the relative weight of the heart and decrease in the rate of pressure development in the isovolumic heart. During oxidative stress induced by addition of 100 µM H2O2 to the perfusate, the decrease in contractile function was more pronounced that in the control. Our results indicate that administration of atorvastatin is accompanied by a decrease in myocardial contractility, which becomes more pronounced under conditions of oxidative stress.
- 1 April 2007
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 143 (4) , 408-410
Effect of β-hydroxy-β-methylglutaryl coenzyme a reductase inhibitor atorvastatin on contractility of the isolated rat heart under normal conditions and during oxidative stress
Long-term administration of β-hydroxy-β-methylglutaryl coenzyme A reductase inhibitor atorvastatin to rats was accompanied by an increase in the relative weight of the heart and decrease in the rate of pressure development in the isovolumic heart. During oxidative stress induced by addition of 100 µM H2O2 to the perfusate, the decrease in contractile function was more pronounced that in the control. Our results indicate that administration of atorvastatin is accompanied by a decrease in myocardial contractility, which becomes more pronounced under conditions of oxidative stress.
- 1 August 2005
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 140 (2) , 181-183
Effect of Ubiquinone Q10 and Antioxidant Vitamins on Free Radical Oxidation of Phospholipids in Biological Membranes of Rat Liver
- 1 August 2005
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 140 (2) , 181-183
Effect of Ubiquinone Q10 and Antioxidant Vitamins on Free Radical Oxidation of Phospholipids in Biological Membranes of Rat Liver